Search

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission will open from May 2 to 9, 2025 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.

Read more

EHA-AHA Hematology Tutorial on Lymphoid Malignancies

Dates: October 18-20, 2019
Location: Yerevan, Armenia
Chairs: G Gaidano, S Danielyan, Y Hakobyan

2019 marks the 3rd time EHA is organizing a tutorial in collaboration with the Armenian Hematology Association (AHA), this time on “Lymphoid Malignancies”.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Granulocytes & Constitutional Marrow Failures Disorders

The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…

Read more